Bli medlem
Bli medlem

Du är här

2020-10-29

Attana receives an instrument order from global pharma company

In March 2018, Attana announced the order of a smaller contract research project from a global pharma company. Following the success of several smaller research projects the customer has today placed an order for an Attana Cell™ 250 instrument. The order will affect the company's cashflow and earnings in Q4 2020 and Q1 2021.

"We are always happy to receive new orders, but we are particularly proud that this order comes from an existing contract research customer, validating our core offering. This illustrates what a small contract research project can lead to when we deliver high quality research and the customer appreciates the value of our technology and competence," comments Teodor Aastrup, CEO Attana.

Författare Attana

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.